Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network

This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the en...

Descripción completa

Detalles Bibliográficos
Autores principales: Bukkems, Vera, Necsoi, Coca, Tenorio, Carmen Hidalgo, Garcia, Coral, Rockstroh, Jürgen, Schwarze-Zander, Caroline, Lambert, John S, Burger, David, Konopnicki, Deborah, Colbers, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744974/
https://www.ncbi.nlm.nih.gov/pubmed/32330231
http://dx.doi.org/10.1093/cid/ciaa488
_version_ 1783624523554226176
author Bukkems, Vera
Necsoi, Coca
Tenorio, Carmen Hidalgo
Garcia, Coral
Rockstroh, Jürgen
Schwarze-Zander, Caroline
Lambert, John S
Burger, David
Konopnicki, Deborah
Colbers, Angela
author_facet Bukkems, Vera
Necsoi, Coca
Tenorio, Carmen Hidalgo
Garcia, Coral
Rockstroh, Jürgen
Schwarze-Zander, Caroline
Lambert, John S
Burger, David
Konopnicki, Deborah
Colbers, Angela
author_sort Bukkems, Vera
collection PubMed
description This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (C(trough)) was reduced by 77%, with 85% of pregnant women having a C(trough) below the effective concentration (EC(90)). Clinical Trials Registration. NCT00825929.
format Online
Article
Text
id pubmed-7744974
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77449742020-12-22 Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network Bukkems, Vera Necsoi, Coca Tenorio, Carmen Hidalgo Garcia, Coral Rockstroh, Jürgen Schwarze-Zander, Caroline Lambert, John S Burger, David Konopnicki, Deborah Colbers, Angela Clin Infect Dis Online Only Articles This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (C(trough)) was reduced by 77%, with 85% of pregnant women having a C(trough) below the effective concentration (EC(90)). Clinical Trials Registration. NCT00825929. Oxford University Press 2020-04-24 /pmc/articles/PMC7744974/ /pubmed/32330231 http://dx.doi.org/10.1093/cid/ciaa488 Text en © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Online Only Articles
Bukkems, Vera
Necsoi, Coca
Tenorio, Carmen Hidalgo
Garcia, Coral
Rockstroh, Jürgen
Schwarze-Zander, Caroline
Lambert, John S
Burger, David
Konopnicki, Deborah
Colbers, Angela
Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network
title Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network
title_full Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network
title_fullStr Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network
title_full_unstemmed Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network
title_short Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network
title_sort clinically significant lower elvitegravir exposure during the third trimester of pregnant patients living with human immunodeficiency virus: data from the pharmacokinetics of antiretroviral agents in hiv-infected pregnant women (panna) network
topic Online Only Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744974/
https://www.ncbi.nlm.nih.gov/pubmed/32330231
http://dx.doi.org/10.1093/cid/ciaa488
work_keys_str_mv AT bukkemsvera clinicallysignificantlowerelvitegravirexposureduringthethirdtrimesterofpregnantpatientslivingwithhumanimmunodeficiencyvirusdatafromthepharmacokineticsofantiretroviralagentsinhivinfectedpregnantwomenpannanetwork
AT necsoicoca clinicallysignificantlowerelvitegravirexposureduringthethirdtrimesterofpregnantpatientslivingwithhumanimmunodeficiencyvirusdatafromthepharmacokineticsofantiretroviralagentsinhivinfectedpregnantwomenpannanetwork
AT tenoriocarmenhidalgo clinicallysignificantlowerelvitegravirexposureduringthethirdtrimesterofpregnantpatientslivingwithhumanimmunodeficiencyvirusdatafromthepharmacokineticsofantiretroviralagentsinhivinfectedpregnantwomenpannanetwork
AT garciacoral clinicallysignificantlowerelvitegravirexposureduringthethirdtrimesterofpregnantpatientslivingwithhumanimmunodeficiencyvirusdatafromthepharmacokineticsofantiretroviralagentsinhivinfectedpregnantwomenpannanetwork
AT rockstrohjurgen clinicallysignificantlowerelvitegravirexposureduringthethirdtrimesterofpregnantpatientslivingwithhumanimmunodeficiencyvirusdatafromthepharmacokineticsofantiretroviralagentsinhivinfectedpregnantwomenpannanetwork
AT schwarzezandercaroline clinicallysignificantlowerelvitegravirexposureduringthethirdtrimesterofpregnantpatientslivingwithhumanimmunodeficiencyvirusdatafromthepharmacokineticsofantiretroviralagentsinhivinfectedpregnantwomenpannanetwork
AT lambertjohns clinicallysignificantlowerelvitegravirexposureduringthethirdtrimesterofpregnantpatientslivingwithhumanimmunodeficiencyvirusdatafromthepharmacokineticsofantiretroviralagentsinhivinfectedpregnantwomenpannanetwork
AT burgerdavid clinicallysignificantlowerelvitegravirexposureduringthethirdtrimesterofpregnantpatientslivingwithhumanimmunodeficiencyvirusdatafromthepharmacokineticsofantiretroviralagentsinhivinfectedpregnantwomenpannanetwork
AT konopnickideborah clinicallysignificantlowerelvitegravirexposureduringthethirdtrimesterofpregnantpatientslivingwithhumanimmunodeficiencyvirusdatafromthepharmacokineticsofantiretroviralagentsinhivinfectedpregnantwomenpannanetwork
AT colbersangela clinicallysignificantlowerelvitegravirexposureduringthethirdtrimesterofpregnantpatientslivingwithhumanimmunodeficiencyvirusdatafromthepharmacokineticsofantiretroviralagentsinhivinfectedpregnantwomenpannanetwork

Ejemplares similares